Satis Group and INVO BioScience intend to open own network of infertility treatment clinics

Ten post jest także dostępny w języku: polski

Satis Group, a Warsaw Stock Exchange-listed business, is nearing an agreement with INVO BioScience, an American firm that has created an innovative assisted reproduction technology. The Satis Group plans to build clinics dealing with infertility treatment utilizing the innovative INVOCell technique in Poland (and other Central and Eastern European countries). According to the EPAF (European Policy Audit on Fertility) data, 1.5 million couples in Poland alone may be dealing with infertility issues.

The letter of intent signed by the Companies concerns the intention to sign an investment agreement and a joint-venture company. The newly formed company, which will be owned by Satis Group and INVO BioScience, will operate a network of clinics dedicated to infertility treatment using, among other things, the innovative INVOCell technology – the first FDA-authorized intravaginal incubation (IVC) system in the United States. It is an innovative technology and technique that offers a more natural, safe, effective and affordable infertility treatment.

Prior to the signing of the letter of intent, the two companies were in advanced negotiations following the conclusion of a non-disclosure agreement, which took place on May 14 this year. Prior to the negotiations, Satis Group completed a transaction to acquire a stake in INVO Bioscience representing nearly 2.4% of its share capital. The transaction was financed under an agreement with Polish American Investment Fund LLC, which was concluded on April 29 this year.

– Our clinics will be the first in Poland to offer infertility treatment using the innovative INVOCell method. It complements other proven methods, including first of all IVF. Our clinics will offer a wide range of treatments, also in other fields than infertility. We are currently developing an extensive budget for the establishment and operation of the first facility in the initial periods. After approval by INVO BioScience and concluding an investment agreement we will start implementing the project – informs Marcin Hańczaruk, Vice President of Satis Group.